Implementing Precision Medicine in cOmmunity HospiTALs

Inclusion Criteria:

Participants are eligible to be included in the study only if they meet all of the following criteria:

1. Age ≥ 18 years

2. Histology: solid malignant tumor

3. Locally advanced/unresectable and/or metastatic (for prostate cancer: castrationresistant prostate cancer, for RH+/HER2- breast cancer: prior treatment withendocrine therapy plus anti-CDK4/6 inhibitor)

4. Eastern Cooperative Oncology Group (ECOG) performance status < 2

5. Measurable disease as per RECIST criteria

6. Patient with a social security in compliance with the French law relating tobiomedical research (Article L.1121-11 of French Public Health Code)

7. Voluntary signed and dated written informed consent prior to any study specificprocedure.

Exclusion Criteria:

Participants will be excluded from the study if they meet any of the following criteria:

1. Radiological evidence of symptomatic or progressive brain metastases

2. Previous or current malignancies of others histologies within the last 2 years, withthe exception of in situ carcinoma of the cervix, and adequately treated basal cellor squamous cell carcinoma of the skin and prostate cancer

3. Any condition which in the Investigator's opinion makes it undesirable for thesubject to participate in a clinical trial or which would jeopardize compliance withthe protocol

4. Patient under guardianship or deprived of his liberty by a judicial oradministrative decision or incapable of giving its consent

5. Minors (Age < 18 years)

6. Pregnant or breast-feeding women

7. Previous enrollment in the present study.